Axim Biotechnologies Inc (AXIM)

[Devolution]

I don't think an annual fee of $5,672 is anything to be concerned about.

Truly the very least of Axim's worries.

When it comes to the DED line, I believe John H. has that well under control, and it is just a matter of time before the revenues start to flow and the increase in pps follows.

I believe DED line revenues will begin this month (March 2022) and will show on the Q1 10-Q (due out May 15), but won't be anything to speak of (I'm guessing no more than $50,000). Q2 would see that move more into the low 100s of thousands, Q3 into the millions, and by end of year into the 10s of millions.

Just my gut feeling, nothing more, and if I am wrong, it won't be the first time (but even a Blind Squirrel finds a nut every once in a while).

Lately I have seen more and more Dry Eye Disease Commercials from Novartis:

https://www.fiercepharma.com/marketing/novartis-introduces-inflammation-villain-character-its-first-xiidra-dry-eye-dtc-campaign

Truly perfect timing for Axim to come out with its patented, 10 to 15 minute results, inexpensive, easy to use by physicians (requires the collection of a tear drop), etc. test kits.

Axim's DED line of test kits are going to revolutionize the diagnostics of DED and cut the cost to physicians dramatically, as well as enable the physician to give a definitive diagnosis right then and there, in the doctor's office, rather than have to wait days for laboratory results.

That is what is meant by "light years ahead of industry competitors" in the following quote from the most recent (February 15th) Press Release:

“After extensive due diligence, we fully expect our supply agreement with IUL will enable us to transform the DED diagnostic testing market with the highest quality readers available and an approach that is light years ahead of industry competitors,” said John Huemoeller, CEO of AXIM Biotech. “We have the only FDA-cleared quantitative test for Dry Eye Disease and believe that it has tremendous accuracy and convenient ease of use for ophthalmologists as well as frontline optometrists. Barry will be instrumental in assisting us to navigate our field study and regulatory approval process.”

The DED line is well on its way to success, and I still feel it will bring AXIM to $2.50 to $3 by year end.

...if only we could get that EUA for Immunopass. THEN we could very well see AXIM at twice those numbers...